The 20 references in paper Alexey Ehrlich D., А. Эрлих Д. (2018) “ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ. ВОЗМОЖНОСТИ ИСПОЛЬЗОВАНИЯ РИВАРОКСАБАНА // ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN” / spz:neicon:aterotromboz:y:2018:i:2:p:68-74

1
Глобальный доклад по диабету Всемирной организации здравоохранения 2016 года. Доступно по ссылке http://www.who.int/diabetes/global-report/ru/. [World Health organization Global Report on Diabetes 2016. Available at http://www.who.int/diabetes/global-report/ ru/.] (In Russ).
(check this in PDF content)
2
Frieberg J., scharling H., Gadsball n. et al. sex-specific increase in prevalence of atrial fibrillation (the Copenhagen City Heart study). Am J Cardiol. 2003; 92: 1419-1423.
(check this in PDF content)
3
Marten s., Keller L., Helmert s., Michalski F., Werth s., sahin K., tittl L., Beyer-Westendorf J. effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden noAC Registry. Thromb Haemost. 2016 May 2; 115(5): 939-49.
(check this in PDF content)
4
Huxley R.R., Filion K.B., Konety s., Alonso A. Metaanalysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108: 56–62.
(check this in PDF content)
5
Kato t., Yamashita t., sekiguchi A. et al. What are arrhythmogenic substrates in diabetic rat atira&. J Cardiovasular Electrophysiol. 2006; 17: 890-894:
(check this in PDF content)
6
tadic M., Cuspidi C. type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Archives of Cardiovascular diseases. 2015; 108(4): 269-276.
(check this in PDF content)
7
Lu Z., Liu n., Bai R. et al. HbA1c levels as predictors of ablation outcome in tipe 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz. 2014; 23.
(check this in PDF content)
8
Klem I., Wehinger C., schneider B., Hartl e., Finsterer J., stollberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. diabetes metab res rev. 2003; 19: 320–328.
(check this in PDF content)
9
Du X., ninomiya t., de Galan B., Abadir e., Chalmers J., Pillai A., Woodward M., Cooper M., Harrap s., Hamet P., Poulter n., Lip G.Y., Patel A. ADVAnCe Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVAnCe study. Eur Heart J. 2009; 30(9): 1128-35.
(check this in PDF content)
10
Afkarian M., sachs M.C., Kestenbaum B., Hirsch I.B., tuttle K.P. Himmelfarb J., de Boer I. Kidney Disease and Increased Mortality Risk in type 2 Diabetes. J Am Soc nephrol. 2013 Jan 31; 24(2): 302–308.
(check this in PDF content)
11
olesen J.B., Lip G., Kamper A.L., Hommel K., Køber L., Lane D.A., Lindhardsen J., Gislason G.H. and torp-Pedersen C. stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. n Engl J med. 2012; 367: 625-635.
(check this in PDF content)
12
Lip G., Frison L., Halperin J.L., Lane D.A. Comparative Validation of a novel Risk score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation the HAs-BLeD (Hypertension, Abnormal Renal/Liver Function, stroke, Bleeding History or Predisposition, Labile InR, elderly, Drugs/Alcohol Concomitantly) score. JACC. 2011; 57(2): 173-180.
(check this in PDF content)
13
2016 esC Guidelines for the management of atrial fibrillation developed in collaboration with eACts the task Force for the management of atrial fibrillation of the european society of Cardiology (esC) Developed with the special contribution of the european Heart Rhythm Association (eHRA) of the esC. European Heart Journal doi:10.1093/eurheartj/ehw210.
(check this in PDF content)
14
Brown J.D., shewale A.R., talbert J.C. Adherence to Rivaroxaban, Dabigatran, and Apixaban for stroke Prevention in Incident, treatment-naïve nonvalvular Atrial Fibrillation. J manag Care Spec Pharm. 2016; 22(11): 1319 - 29.
(check this in PDF content)
15
Patel M.R., Mahaffey K.W., Garg I., Pan G., singer D.e., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., nessel C.C. et al., for the RoCKet AF Investigators. Rivaroxaban versus Warfarin in nonvalvular Atrial Fibrillation. n Engl J med. 2011; 365: 883-891.
(check this in PDF content)
16
Bansilal s., Bloomgarden Z., Halperin J.L., Hellkamp A.s., Lokhnygina Y., Patel M.R., Becker R.s., Breithardt G., Hacke W., Hankey G.L., nessel C.C., singer D.e., Berkowitz s.D., Piccini J.P., Mahaffey K.W., Fox K.A.A., on behalf of the RoCKet AF steering Committee and Investigators. efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban once-daily, oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of stroke and embolism trial in Atrial Fibrillation (RoCKet AF trial). Am Heart J. 2015; 170: 675-682.e8.
(check this in PDF content)
17
Peacock W.F., tamayo s., sicignano n., Hopf K.P., Yuan Z. and Patel M. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017; 119: 753-759.
(check this in PDF content)
18
Coleman C.I., Bunz t.J., eriksson D., Meinecke A.-K., sood n.A. effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. diabetic medicine. 2018; 35 (8): 1105-1110.
(check this in PDF content)
19
Инструкция к использованию препарата Ксарелто. Доступно по ссылке http://grls.rosminzdrav.ru/Default. aspx. [Instructions for use of Xarelto. Available at http:// grls.rosminzdrav.ru/Default.aspx.] (In Russ).
(check this in PDF content)
20
Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32: 2387–2394.
(check this in PDF content)